Device China DeviceChina - Home 中文版 zhuce showcase Frequently Asked Questions 主页 English Language 注册参会 路演报名 疑问解答






Since our founding in 1949 by Earl Bakken, Medtronic has put people first. We strive to alleviate pain, restore health, and extend life. To meet the needs of patients and healthcare professionals around the globe, Medtronic operates from more than 260 locations in more than 155 countries. Committed to helping to transform healthcare.For more information, visit us at:


Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages over USD$11 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 170 private companies across a wide range of therapeutic categories and stages of development, over 90 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well, with ~27×cumulative return in the past 20 years. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund, with approximately USD$200 million under management. OAP has made investments in 20 companies. 




Frontline BioVentures is a premier venture capital firm based in China, with offices in Shanghai, Suzhou, and Hong Kong. We specialize in investment of innovative life sciences companies with business focuses on strategic areas promoted by the Chinese government for growth and development.

Our investment professionals have proven track records both domestically and overseas and have valuable resources and extensive experiences in nurturing and scaling venture startups. We are intimately familiar with the landscape of pharma, biotech and medtech industry in the country.

We have a combined 85 years of experiences in the field of life sciences. Prior to Frontline BioVentures, our partners were venture capitalists, scientists, and serial entrepreneurs. Our team of seasoned professionals has a unique investment sense with a principled investment process that enables us to seize early signals for the next trend of the industries and stand ahead of curve.

In addition, we have accumulated a broad network of close ties with government agencies, CFDA, universities, research institutes, hi-tech parks, other institutional investors, domestic and multinational pharmaceutical and medtech companies, and leading venture capital firms in more established markets like the United States and Europe.

Our advisors are among the most respectable and senior specialists in life sciences who have built billion-dollar companies. Their domain expertise and networks provide Frontline BioVentures with competitive advantages in accessing capable and committed entrepreneurs and high quality deals, and maximizing the chance for our portfolio companies to succeed. 


Sungent bioVENTURE was founded in Suzhou bioBAY on September 9th 2013 with a vision to be the best healthcare dedicated venture capital in China,

Our team manages approximately USD 90 Million of the 1st phase of fund, with distinguished scientific, medical, investment and extensive professional experience and tacking records in the healthcare industry.

The bioBAY, one of our leading investors own the best incubator and platform for life sciences start-ups in China, by levering the rich resources of bioBAY, we take more advantages and opportunities for investment continually.

Up to now, the excellent results on return of investment have been achieved from the previously invested startups, which are encouraging us to be the best venture capital firm for healthcare in China.

Dedicated for startups with growth potential, form biopharmaceuticals,medical devices, in-vitro diagnostics, to healthcare services, Sungent bioVENUTE is scouting the life sciences and healthcare industry for innovations that will bring people in better health and live longer.